Reducing medication errors and increasing patient safety: Case studies in clinical pharmacology

Journal of Clinical Pharmacology

Volumn 43, Issue 7, 2003, Pages 768-783

  Benjamin, David M ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

High risk drugs; Medication errors; Patient safety; System errors

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRAZOLAM; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CEPHALOSPORIN DERIVATIVE; CIMETIDINE; CYCLOPHOSPHAMIDE; DIAZEPAM; DIHYDROXYALUMINUM SODIUM CARBONATE; DIPHENHYDRAMINE; FELODIPINE; HEPARIN; ISOSORBIDE DINITRATE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PENICILLIN G; PETHIDINE; POTASSIUM CHLORIDE; POTASSIUM DIHYDROGEN PHOSPHATE; PROCHLORPERAZINE MALEATE; PROMETHAZINE; SODIUM CHLORIDE; TERAZOSIN; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; TUMS; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALLERGIC REACTION; ANAPHYLAXIS; CLINICAL ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; CONFERENCE PAPER; ERROR; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LAW; MALE; MEDICAL LIABILITY; ORTHOSTATIC HYPOTENSION; PATIENT RIGHT; QUALITY CONTROL; RASH; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UNITED STATES; URTICARIA;

EID: 0038650500     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003254794     Document Type: Conference Paper

References (66)

1. Adams D: State error legislation gets mixed reviews. Am Med News 2001 July 30;10, 12.
2. Institute of Medicine: To Err Is Human: Building a Safer Health System. Washington, DC: National Academy Press, 1999.
3. McDonald CJ, Weiner M, Hui SI: Deaths due to medical errors are exaggerated in Institute of Medicine report. JAMA 2000;284:93-95.
4. Leape LL: Institute of Medicine medical error figures are not exaggerated. JAMA 2000;284:95-97.
5. Beckman HB, Markakis KM, Suchman AL, et al: The doctor-patient relationship and malpractice: lessons from plaintiff depositions. Arch Intern Med 1994;154:1365-1370.
6. Benjamin DM: Reducing medication errors and increasing patient safety through better communication. Focus on Patient Safety 2001;4:6-8.
7. Slater v. Baker & Stapleton, 2 Wils. K.B. 359, 95 Eng. Rep. 860 (1767).
8. McCold AH: A reappraisal of liability for unauthorized medical treatment. Minn Law Rev 1957;41(381):434.
9. 95 Minn. 261,104 N.W. 12 (1905).
10. Mazur DJ: What should patients be told prior to a medical procedure? Ethical and legal perspectives on medical informed consent. Am J Med 1986;81:1051-1054.
11. Black's Law Dictionary. Abridged 5th ed. New York: The West Group, 1983.
12. Schloendorff v. Society of NY Hospital, 211 N.Y. 125, 105 N.E. 92 (1914).
13. Benjamin DM: Driving under the influence of medications: are physicians and pharmacists adequately informing their patients of the risks of medication use? News and Views (Newsletter of the Toxicology Section of the American Academy of Forensic Sciences) 2002 May; http://www.aafs.org/News&Views/DrivingUnder.htm
14. Benjamin DM: Communicating with patients about adverse drug reactions. Drug Therapy 1994;24:36-38.
15. Benjamin DM: Alpha blockers and the law. Proceedings of the American Academy of Forensic Sciences 1998 February;146-147.
16. Garcia-Doval I, LeCleach L, Bocquet H, et al: Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323-327.
17. Sterns RS: Improving the outcome of patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol 2000;136:410-411.
18. Moriarty MP: Medical/legal issues in regional anesthesia. American Society of Regional Anesthesia (ASRA) NEWS 1991 August;4-7.
19. Prager LO: Jury blames doctor's bad penmanship for patient death. Am Med News 1999 Nov 22-29;1, 30-31.
20. Physicians' Desk Reference. 56th ed. Montvale, NJ: Medical Economics, 2002.
21. Poor handwriting on scrip brings negligence ruling. Healthcare Risk Management 2000 Jan;6-8.
22. HRC Risk Analysis. Vol. 4. Plymouth, PA: ECRI, 2000.
23. Dunn EB, Wolfe JJ: Let go of Latin! Vet Human Toxicol 2001;43:235-236.
24. Bates DW, Boyle DL, Laird N, et al: Incidence of adverse drug events and potential adverse drug events. JAMA 1995;274(1):29-34.
25. Leape LL, Bates DW, Cullen DJ, et al: Systems analysis of adverse drug events. JAMA 1995;274(1):35-43.
26. Benjamin DM, Pendrak RF: Medication errors: an analysis comparing PHICO's closed claims data and PHICO's Event Reporting Trending System (PERTS). J Clin Pharmacol 2003;43:754-759.
27. Santell JP, Hicks RW, McMeeking J, Cousins DD: Medication errors: experience of the United States Pharmacopeia (USP) MEDMARX reporting system. J Clin Pharmacol 2003;43:760-767.
28. Bates DW, Leape LL, Cullen DJ, et al: Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998;280(15):1311-1316.
29. Chin T: New players in electronic prescribing. Am Med News 2002 Feb 25;21, 23.
30. Cannistra J: Bar code project eliminates medication errors. Pharmacy Today 2002 August;27.
31. Joint Commission on Accreditation of Healthcare Organizations (JCAHO): Sentinel event alert: high-alert medications and patient safety. Report, issue 11, November 19, 1999.
32. Barker KN, Flynn EA, Pepper GA, et al: Medication errors observed in 36 health care facilities. Arch Intern Med 2002;162:1897-1903.
33. Bates DW, Spell N, Cullen DJ, et al: The cost of adverse drug events in hospitalized patients. JAMA 1997;277(4):307-311.
34. Bates DW, Boyle DL, Vander Vliet MB, et al: Relationship between medication errors and adverse drug events. J Gen Intern Med 1995;10(4):199-205.
35. Evans RS, Pestonik SL, Classen DC, et al: Prevention of adverse drug events through computerized surveillance. Proc Annu Symp Comput Appl Med Care 1992;437-441.
36. Thomas EJ, Studdert DM, Burstin HR, et al: Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care 2000;38(3):261-271.
37. Lesar TS, Briceland L, Cullen DJ, et al: Factors related to errors in medication prescribing. JAMA 1997;277(4):312-317.
38. Hardman JG, Limbird LE (eds.): The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, 1996.
39. Pharmacokinetic dosing for aminoglycosides. Med Sci Bull 1988;11(4):1-2.
40. O'Donnell JT: Coumadin Rx error results in $722,500 verdict. Drug Topics 1992 March 23;64.
41. O'Donnell JT: Adverse effects of corticosteroids. J Pharmacy Practice 1989;11(4):256-266.
42. Byny RL: Withdrawal from glucocorticoid therapy. NEJM 1976;295:30-32.
43. Good AE: Bilateral aseptic necrosis of femur following a 16-day course of corticotropin. JAMA 1974;228:497.
44. Mankin HJ: Nontraumatic necrosis of bone (osteonecrosis). NEJM 1992;326:1473-1478.
45. Ray WA, Griffin MR, Avorn J: Evaluating drugs after their approval for clinical use. NEJM 1993;329:2029-2032.
46. United States General Accounting Office: FDA Drug Review: Postapproval Risks. Washington, DC: Government Printing Office, 1976-1985.
47. Benjamin DM: The pharmacoepidemiology of adverse drug reactions: the "first year effect" or expansion of the denominator. Proceedings of the Drug Information Association 1994 June 7;146-147.
48. Stephens MDB: The detection of new adverse drug reactions. Drug Info J 1993;27:1037.
49. Blum RS: Legal considerations in off-label medication prescribing. Arch Intern Med 2002;162:1777-1779.
50. Robinson DS, Benjamin DM, McCormack JJ: Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther 1971;12:491-495.
51. Aggler PM, O'Reilly RA, Leong L, et al: Potentiation of anticoagulant effect of warfarin by phenylbutazone. NEJM 1967;276:496-501.
52. Parkinson A: An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996;24:45-57.
53. Benjamin DM, Buckman RW: Minimizing the risk of adverse drug interactions. The Female Patient 1996;21:47-61.
54. Back DJ, Orme M L'E: Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18:472-484.
55. Ferslew KE, Hagardorn AN, Harlan GC, et al: A fatal interaction between clozapine and fluoxetine. J Forensic Sci 1998;43:1082-1085.
56. Goeringer KE, Raymon L, Christian GD, et al: Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. J Forensic Sci 2000;45:633-648.
57. Thursby K; Should you give patients what they want, even if they don't need it? Am Med News 2002 Sept 2;23.
58. Wilkes MS, Doblin BH, Shapiro MF: Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med 1992;116:912-919.
59. Leape LL, Woods DD, Hatlie MJ, et al: Promoting patient safety by preventing medical error. JAMA 1998;280:1444.
60. Leape LL, Bates DW, Cullen DJ, et al: System analysis of adverse drug events. JAMA 1995;274:35-43.
61. Singer DRJ, MacGregor GA: Angioneurotic oedema associated with two angiotensin converting enzyme inhibitors [Letter]. Brit Med J 1986;293:1243.
62. Dean DE, Schultz DL, Powers RH: Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci 2001;46:1239-1243.
63. Leape LL, Cullen DJ, Clapp MD, et al: Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1997;82:267-270.
64. Benjamin DM, Fritz G, Lieberman S, et al: Risk Management PEARLS for Medication Error Reduction. Chicago: American Society for Healthcare Risk Management, 2001.
65. American Society for Healthcare Risk Management: Strategies and Tips of Maximizing Failure Mode Effect Analysis in Your Organization. Chicago: American Society for Healthcare Risk Management, 2002.
66. Taxonomy of Medication Errors. Rockville, MD: National Coordinating Council for Medication Error Reporting and Prevention, 1998.